Patrick Urban

2.3k total citations · 1 hit paper
31 papers, 1.2k citations indexed

About

Patrick Urban is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Patrick Urban has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Patrick Urban's work include Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). Patrick Urban is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). Patrick Urban collaborates with scholars based in Switzerland, United States and Spain. Patrick Urban's co-authors include Cristian Massacesi, Emmanuelle di Tomaso, Urs Eppenberger, Serenella Eppenberger‐Castori, Vincent Vuaroqueaux, Martin Labuhn, Enriqueta Felip, Alice T. Shaw, Tony Mok and Giorgio V. Scagliotti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Patrick Urban

31 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 412 citations Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Urban Switzerland	13	746	665	560	255	138	31	1.2k
Fabrice Branle Switzerland	15	951 1.3×	796 1.2×	578 1.0×	209 0.8×	150 1.1×	36	1.5k
Roberta Caputo Italy	13	805 1.1×	664 1.0×	612 1.1×	317 1.2×	89 0.6×	27	1.4k
Olga Rodríguez Spain	5	821 1.1×	615 0.9×	683 1.2×	235 0.9×	224 1.6×	8	1.4k
Caroline Germa United States	16	745 1.0×	566 0.9×	364 0.7×	217 0.9×	238 1.7×	54	1.1k
Heidi Savage United States	12	731 1.0×	389 0.6×	801 1.4×	489 1.9×	138 1.0×	23	1.4k
María G. Kuba United States	14	773 1.0×	445 0.7×	897 1.6×	370 1.5×	184 1.3×	20	1.5k
Cataldo Bianco Italy	24	765 1.0×	427 0.6×	757 1.4×	252 1.0×	128 0.9×	37	1.5k
S. Gail Eckhardt United States	14	779 1.0×	470 0.7×	686 1.2×	302 1.2×	66 0.5×	46	1.3k
Mirko Marabese Italy	23	822 1.1×	638 1.0×	913 1.6×	369 1.4×	60 0.4×	54	1.6k
Angelica Fasolo Italy	18	856 1.1×	390 0.6×	674 1.2×	284 1.1×	105 0.8×	43	1.5k

Countries citing papers authored by Patrick Urban

Since Specialization

Citations

This map shows the geographic impact of Patrick Urban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Urban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Urban more than expected).

Fields of papers citing papers by Patrick Urban

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Urban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Urban. The network helps show where Patrick Urban may publish in the future.

Co-authorship network of co-authors of Patrick Urban

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Urban. A scholar is included among the top collaborators of Patrick Urban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Urban. Patrick Urban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Daniel S.W., Michael Thomas, Dongwook Kim, et al.. (2021). Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung Cancer. 163. 7–13. 7 indexed citations

Lau, Yvonne, et al.. (2019). Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients. Cancer Chemotherapy and Pharmacology. 84(3). 501–511. 5 indexed citations

Pistilli, Barbara, Timothy Pluard, Ander Urruticoechea, et al.. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168(2). 357–364. 50 indexed citations

Shaw, Alice T., Tae Min Kim, Lucio Crinò, et al.. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 18(7). 874–886. 412 indexed citations breakdown →

Scagliotti, Giorgio V., Lucio Crinò, Geoffrey Liu, et al.. (2016). Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Annals of Oncology. 27. vi579–vi579. 22 indexed citations

Massacesi, Cristian, Emmanuelle di Tomaso, Patrick Urban, et al.. (2016). PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy. 9. 203–203. 195 indexed citations

Mok, Tony, Giorgio V. Scagliotti, Lucio Crinò, et al.. (2016). 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ). Annals of Oncology. 27. ix142–ix143. 1 indexed citations

Martín, Miguel, Luc Dirix, Joyce O’Shaughnessy, et al.. (2016). A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Annals of Oncology. 28(2). 313–320. 136 indexed citations

Iwata, Hiroji, José Baselga, Mario Campone, et al.. (2013). Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology. 31(15_suppl). TPS650–TPS650. 8 indexed citations

10.

Martin, Michael, Suzette Delaloge, Luc Dirix, et al.. (2013). Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4. Cancer Research. 73(24_Supplement). OT2–6. 3 indexed citations

11.

Kelly, Kevin R., Markus Zollinger, Eugene Tan, et al.. (2012). Metabolism of patupilone in patients with advanced solid tumor malignancies. Investigational New Drugs. 31(3). 605–615. 2 indexed citations

12.

Campone, Mario, P. Fumoleau, Marta Gil-Martín, et al.. (2012). Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. Cancer Research. 72(24_Supplement). P6–11. 2 indexed citations

13.

Tsimberidou, Apostolia M., Nancy Lewis, Tony Reid, et al.. (2011). Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 68(6). 1507–1516. 6 indexed citations

14.

Melichar, Bohuslav, E. Casado, Jaafar Bennouna, et al.. (2011). Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. British Journal of Cancer. 105(11). 1646–1653. 16 indexed citations

15.

Vuaroqueaux, Vincent, Patrick Urban, Martin Labuhn, et al.. (2007). Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Research. 9(3). R33–R33. 52 indexed citations

16.

Cicenas, Jonas, Patrick Urban, Willy Küng, et al.. (2006). Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. European Journal of Cancer. 42(5). 636–645. 56 indexed citations

17.

Zanetti‐Dällenbach, Rosanna, Vincent Vuaroqueaux, Edward Wight, et al.. (2006). Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Breast Cancer Research. 8(4). R51–R51. 15 indexed citations

18.

Urban, Patrick, Vincent Vuaroqueaux, Martin Labuhn, et al.. (2006). Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer. Journal of Clinical Oncology. 24(26). 4245–4253. 52 indexed citations

19.

Cicenas, Jonas, Patrick Urban, Vincent Vuaroqueaux, et al.. (2005). Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Research. 7(4). R394–401. 51 indexed citations

20.

Kurtz, B., et al.. (1996). MR-mammographische Beurteilung des Tumoransprechverhaltens nach neoadjuvanter Radiochemotherapie lokal fortgeschrittener Mammakarzinome. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 164(6). 469–474. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact